CA2365533A1 - Diagnosis and treatment of neuroectodermal tumors - Google Patents
Diagnosis and treatment of neuroectodermal tumors Download PDFInfo
- Publication number
- CA2365533A1 CA2365533A1 CA002365533A CA2365533A CA2365533A1 CA 2365533 A1 CA2365533 A1 CA 2365533A1 CA 002365533 A CA002365533 A CA 002365533A CA 2365533 A CA2365533 A CA 2365533A CA 2365533 A1 CA2365533 A1 CA 2365533A1
- Authority
- CA
- Canada
- Prior art keywords
- chlorotoxin
- tissue
- group
- labeled
- neoplastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides fusion proteins for the detection and treatme nt of neuroectodermal tumors. Previous work demonstrated that chlorotoxin is specific for glial-derived or meningioma-derived tumor cells. The current invention has extended the use of chlorotoxin-cytotoxin fusion proteins to treat the whole class neuroectodermal tumors such as gliomas, meningiomas, ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas , melanomas, PPNET's, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain. Also, diagnostic methods are provided for screening neoplastic neuroectodermal tumors.
Claims (14)
1. A method of treating an individual having a neuroectodermal tumor, comprising the step of:
administering a pharmaceutical composition comprising a pharmaceutically effective dose of a neuroectodermal tumor specific ligand fused to a cytotoxic moiety and a pharmaceutically acceptable carrier.
administering a pharmaceutical composition comprising a pharmaceutically effective dose of a neuroectodermal tumor specific ligand fused to a cytotoxic moiety and a pharmaceutically acceptable carrier.
2. The method of claim 1, wherein the neuroectodermal tumor is a tumor type treated is selected from the group consisting of ependymonas, medulloblastomas, neuroblastomas, gangliomas, pheochromocytomas, melanomas, peripheral primitive neuroectodermal tumors, small cell carcinoma of the lung, Ewing's sarcoma, and metastatic tumors in the brain.
3. The method of claim 1, wherein the neuroectodermal tumor specific ligand is chlorotoxin.
4. The method of claim 3, wherein said chlorotoxin is selected from the group consisting of native chlorotoxin, synthetic chlorotoxin and recombinant chlorotoxin.
5. The method of claim 1, wherein said cytotoxic moieties is selected from the group consisting of gelonin, ricin, saponin, pseudonomas exotoxin, pokeweed antiviral protein, diphtheria toxin, and complement proteins.
6. The method of claim 1, wherein the neuroectodermal tumor specific ligand is an antibody against the chlorotoxin receptor.
7. A method of differentiating neuroectodermal tumor-derived neoplastic tumor tissue from non-neoplastic tissue, comprising the steps of:
contacting a tissue of interest with labeled chlorotoxin which binds specifically to neuroectodermal tumor neoplastic tumor tissue; and measuring the binding of the labeled chlorotoxin, wherein an elevated level of binding, relative to normal tissue, indicates that the tissue is neoplastic.
contacting a tissue of interest with labeled chlorotoxin which binds specifically to neuroectodermal tumor neoplastic tumor tissue; and measuring the binding of the labeled chlorotoxin, wherein an elevated level of binding, relative to normal tissue, indicates that the tissue is neoplastic.
8. The method of claim 7, wherein said chlorotoxin is labeled with a detection moiety.
9. The method of claim 8, wherein said detection moiety is selected from the group consisting of a fluroschrome, biotin, a colorimetric agent linked to an enzyme substrate.
10. The method of claim 8, wherein said labeled chlorotoxin binding is determined by a method selected from the group consisting of fluorescent microscopy, ELIZA and fluorescent activated cell sorting.
11. The method of claim 7, wherein said labeled chlorotoxin is radiolabeled.
12. The method of claim 11, wherein said radiolabeled chlorotoxin is selected from the group consisting of 131I-chlorotoxin and 125I-chlorotoxin.
13. The method of claim 7, wherein the level of radiolabeled chlorotoxin binding affinity indicative of neoplastic tissue is from about 5 nanomolar to about 5 micromolar.
14. The method of claim 13, wherein said labeled chlorotoxin binding is determined using positron emission tomography scanning.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/296,031 | 1999-04-21 | ||
US09/296,031 US6667156B2 (en) | 1995-12-27 | 1999-04-21 | Diagnosis and treatment of neuroectodermal tumors |
PCT/US2000/010453 WO2000062807A1 (en) | 1999-04-21 | 2000-04-19 | Diagnosis and treatment of neuroectodermal tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2365533A1 true CA2365533A1 (en) | 2000-10-26 |
CA2365533C CA2365533C (en) | 2012-11-06 |
Family
ID=23140309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2365533A Expired - Lifetime CA2365533C (en) | 1999-04-21 | 2000-04-19 | Diagnosis and treatment of neuroectodermal tumors |
Country Status (10)
Country | Link |
---|---|
US (4) | US6667156B2 (en) |
EP (1) | EP1200123B1 (en) |
JP (1) | JP2002542206A (en) |
CN (1) | CN1377280A (en) |
AT (1) | ATE308340T1 (en) |
AU (1) | AU777209B2 (en) |
CA (1) | CA2365533C (en) |
DE (1) | DE60023706T2 (en) |
ES (1) | ES2253223T3 (en) |
WO (1) | WO2000062807A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
CA2494451A1 (en) * | 2002-05-31 | 2003-12-11 | Transmolecular, Inc. | Treatment of cell proliferative disorders with chlorotoxin |
US20060088899A1 (en) * | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
DE602006020710D1 (en) | 2005-04-22 | 2011-04-28 | Fred Hutchinson Cancer Res Foundation | FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER |
EP1934261B1 (en) * | 2005-09-26 | 2014-10-29 | Medarex, L.L.C. | Human monoclonal antibodies to cd70 |
WO2007117467A2 (en) * | 2006-03-31 | 2007-10-18 | Transmolecular, Inc. | Use of tm-601 for the diagnosis and treatment of tumors |
WO2008074004A2 (en) * | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind cd70 and uses thereof |
AU2008285364A1 (en) * | 2007-08-07 | 2009-02-12 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
WO2009049184A2 (en) * | 2007-10-12 | 2009-04-16 | Transmolecular, Inc. | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
US8097284B2 (en) * | 2007-11-13 | 2012-01-17 | Arthur Mikaelian | Polarized scorpion venom solution and a method for making polarized scorpion venom solution |
CN102438646A (en) * | 2008-05-15 | 2012-05-02 | 特兰斯莫莱库拉公司 | Treatment of metastatic tumors |
EP2300045A1 (en) * | 2008-05-15 | 2011-03-30 | Transmolecular, Inc. | Treatment of metastatic tumors |
KR101923235B1 (en) | 2010-02-04 | 2018-11-28 | 에이자이 아이엔씨. | Chlorotoxin polypeptides and conjugates and uses thereof |
CA2799169C (en) | 2010-05-11 | 2019-07-23 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
US8524239B2 (en) | 2010-07-09 | 2013-09-03 | The United States of America as represented by the Secrectary, Department of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
CN102552943A (en) * | 2010-12-31 | 2012-07-11 | 复旦大学 | Tumor targeting magnetic resonance contrast medium modified by chlorotoxin and preparation method and application thereof |
WO2013003507A1 (en) | 2011-06-27 | 2013-01-03 | Morphotek, Inc. | Multifunctional agents |
WO2014093406A1 (en) | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Methods for screening |
US9784730B2 (en) | 2013-03-21 | 2017-10-10 | University Of Washington Through Its Center For Commercialization | Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
JP6741599B2 (en) | 2014-06-02 | 2020-08-19 | リ−コール,インコーポレイティド | Phthalocyanine probe and its use |
JP6796058B2 (en) | 2014-08-08 | 2020-12-02 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Light-controlled removal of targets in vitro and in vivo |
CN104877016A (en) * | 2015-04-30 | 2015-09-02 | 温州生物材料与工程研究所 | Folded chlorotoxin, chlorotoxin mutant, folded chlorotoxin mutant and preparation process thereof |
US9518099B1 (en) * | 2015-09-13 | 2016-12-13 | Wenzhou Institute Of Biomaterials And Engineering | Refolded chlorotoxin, chlorotoxin variant, refolded chlorotoxin variant, and preparation technology thereof |
JP7409741B2 (en) | 2017-09-15 | 2024-01-09 | エーザイ インク. | Chlorotoxin drugs and their uses |
US11866466B2 (en) | 2017-12-19 | 2024-01-09 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0282581A4 (en) * | 1986-09-19 | 1988-11-02 | Scripps Clinic Res | Monoclonal paratopic molecule directed to human ganglioside gd2. |
CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
US5223253A (en) | 1989-09-28 | 1993-06-29 | American Home Products Corporation | Bovine vaccine compositions and method for preventing trichomonas infections using same |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5756340A (en) | 1995-05-08 | 1998-05-26 | The Regents Of The University Of California | Insect control with multiple toxins |
US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
US5905027A (en) * | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
EP2300045A1 (en) * | 2008-05-15 | 2011-03-30 | Transmolecular, Inc. | Treatment of metastatic tumors |
-
1999
- 1999-04-21 US US09/296,031 patent/US6667156B2/en not_active Expired - Lifetime
-
2000
- 2000-04-19 AT AT00926105T patent/ATE308340T1/en not_active IP Right Cessation
- 2000-04-19 WO PCT/US2000/010453 patent/WO2000062807A1/en active IP Right Grant
- 2000-04-19 CN CN00806560A patent/CN1377280A/en active Pending
- 2000-04-19 ES ES00926105T patent/ES2253223T3/en not_active Expired - Lifetime
- 2000-04-19 AU AU44687/00A patent/AU777209B2/en not_active Expired
- 2000-04-19 CA CA2365533A patent/CA2365533C/en not_active Expired - Lifetime
- 2000-04-19 DE DE60023706T patent/DE60023706T2/en not_active Expired - Lifetime
- 2000-04-19 EP EP00926105A patent/EP1200123B1/en not_active Expired - Lifetime
- 2000-04-19 JP JP2000611943A patent/JP2002542206A/en active Pending
-
2003
- 2003-10-17 US US10/686,782 patent/US7678759B2/en not_active Expired - Fee Related
-
2010
- 2010-02-16 US US12/706,383 patent/US20100215576A1/en not_active Abandoned
-
2012
- 2012-01-19 US US13/354,317 patent/US20120183544A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2000062807A1 (en) | 2000-10-26 |
JP2002542206A (en) | 2002-12-10 |
EP1200123A4 (en) | 2003-05-02 |
EP1200123A1 (en) | 2002-05-02 |
EP1200123B1 (en) | 2005-11-02 |
US6667156B2 (en) | 2003-12-23 |
US20100215576A1 (en) | 2010-08-26 |
US7678759B2 (en) | 2010-03-16 |
CA2365533C (en) | 2012-11-06 |
AU4468700A (en) | 2000-11-02 |
ES2253223T3 (en) | 2006-06-01 |
DE60023706T2 (en) | 2006-08-03 |
US20020146749A1 (en) | 2002-10-10 |
ATE308340T1 (en) | 2005-11-15 |
DE60023706D1 (en) | 2005-12-08 |
AU777209B2 (en) | 2004-10-07 |
US20120183544A1 (en) | 2012-07-19 |
CN1377280A (en) | 2002-10-30 |
US20040141981A1 (en) | 2004-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2365533A1 (en) | Diagnosis and treatment of neuroectodermal tumors | |
Cuttitta et al. | Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer | |
US7033572B2 (en) | Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system | |
JP3443119B2 (en) | Tumor necrosis factor binding ligand | |
Berthiaume et al. | Antibody-targeted photolysis of bacteria in vivo | |
CA2579523A1 (en) | Atad3a-binding molecules for treatment, detection and prevention of cancer | |
WO1997044461A3 (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
CA2451680A1 (en) | Human dr4 antibodies and uses thereof | |
KR920702692A (en) | New antibodies reactive with human carcinoma | |
JP2002527052A5 (en) | ||
Akiyama et al. | Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin | |
HUP0001136A2 (en) | Remedies for lymphocytic tumors | |
AU722722B2 (en) | Concurrent in-vivo immunoconjugate binding to multiple epitopes of vascular permeability factor on tumor-associated blood vessels | |
US5721211A (en) | Compositions and methods for treating small cell and nonsmall cell lung cancers | |
CN111093701A (en) | Antibody drug conjugate containing anti-GLOBO H antibody and application thereof | |
WO1999002545A3 (en) | Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
WO2003035011A2 (en) | Multidrug multiligand conjugates for targeted drug delivery | |
Jung et al. | Biological activity of the antitumor protein neocarzinostatin coupled to a monoclonal antibody by N-succinimidyl 3-(2-pyridyldithio)-propionate | |
CA2449284A1 (en) | Alpha-fetoprotein peptides and uses thereof | |
Fritzsche et al. | Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) from purified plasma membranes of human tumour cell lines as albumin-binding proteins | |
AR016427A1 (en) | USEFUL CONJUGATES FOR THE TREATMENT OF PROSSTATA CANCER, AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM. | |
WO1992018536A3 (en) | Method for detecting an localizing tissues having neurokinine 1 receptors | |
JPH03261800A (en) | Peptide | |
EP0835662A2 (en) | A drug for the treatment of cancer | |
US6156725A (en) | Drug for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200419 |